During the past decade, Kursk Regional Oncology Centre conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 4 clinical trials were completed, i.e. on
average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200%
of trials that started reached the finish line.
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
2017-01-21
2019-11-22
Completed
671
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Kursk Regional Oncology Centre"
#1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator and "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Kursk Regional Oncology Centre
According to Clinical.Site data, the most researched conditions in "Kursk Regional Oncology Centre" are
"Melanoma" (1 trials), "Melanoma (Skin)" (1 trials), "Melanoma Stage III" (1 trials), "Melanoma Stage IV" (1 trials) and "Metastatic Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Kursk Regional Oncology Centre" in a lesser frequency.
Clinical Trials Intervention Types at Kursk Regional Oncology Centre
Most popular intervention types in "Kursk Regional Oncology Centre" are "Biological" (3 trials) and "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Bempegaldesleukin" (1 trials), "Bevacizumab as Avastin" (1 trials), "Bevacizumab as MYL-1402O" (1 trials), "Carboplatin" (1 trials) and "Farletuzumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Kursk Regional Oncology Centre
The vast majority of trials in "Kursk Regional Oncology Centre" are
4 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Kursk Regional Oncology Centre
Currently, there are NaN active trials in "Kursk Regional Oncology Centre".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Kursk Regional Oncology Centre,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Kursk Regional Oncology Centre, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".